Dendreon Pharmaceuticals is a biotechnology company based in the United States that specializes in the development and commercialization of immunotherapy products for the treatment of cancer. The company was founded in 1992 and has its headquarters in Seal Beach, California. One of Dendreon's main products is PROVENGE (sipuleucel-T), which is the first FDA-approved autologous cellular immunotherapy for the treatment of advanced prostate cancer.

PROVENGE works by stimulating a patient's immune system to target and attack prostate cancer cells. The company's mission is to improve the lives of cancer patients by harnessing the power of the immune system. Dendreon operates on a global scale, with various subsidiaries and partnerships.

One of its notable partnerships is with BTG plc, a healthcare company based in the United Kingdom. Under this partnership, BTG handles the commercialization of PROVENGE outside of the United States. In terms of market position, Dendreon is recognized as a leader in the field of immunotherapy for cancer treatment.

PROVENGE has gained significant traction in the market and has been used by thousands of patients worldwide. However, there is strong competition in the immunotherapy sector from other pharmaceutical companies, such as Bristol-Myers Squibb and Merck, who have their own immunotherapy products for various cancers. Over the years, Dendreon has gone through significant changes in its strategy and product lineup.

In 2011, the company faced financial difficulties and filed for bankruptcy. However, in 2012, Dendreon was acquired by Valeant Pharmaceuticals International, which helped stabilize the company and expand its reach. As of the latest updates, Dendreon continues to focus on the development and commercialization of immunotherapy products.

The company remains committed to improving therapies for cancer patients and exploring potential partnerships and collaborations to further advance its research and development efforts. In conclusion, Dendreon Pharmaceuticals is a leading biotechnology company that specializes in immunotherapy for cancer treatment. With its flagship product, PROVENGE, it has established a strong presence in the global market.

The company continues to innovate and collaborate to bring new therapies to cancer patients, contributing to the advancement of cancer treatment worldwide